EHC Program Update: Bipolar Disorder Draft Report; Schizophrenia Final Report; Spanish Consumer Summaries for Omega-3 Fatty Acids and CVD, C. diff, and Insomnia

EHC Program Update: Bipolar Disorder Draft Report; Schizophrenia Final Report; Spanish Consumer Summaries for Omega-3 Fatty Acids and CVD, C. diff, and Insomnia

Opportunity to Comment on Draft Report

We encourage the public to participate in the development of our research projects. Comments can be submitted for:

Treatment for Bipolar Disorder in Adults

Available for comment until November 22, 2017

Evidence Report Now Available

Treatment for Adults With Schizophrenia (Systematic Review, released 10/26/2017)

Selected key findings:

• Olanzapine, aripiprazole, risperidone, quetiapine, and ziprasidone were similar in function, quality of life, mortality, and overall adverse events. Core illness symptoms were better with olanzapine and risperidone than asenapine, quetiapine, and ziprasidone, and with paliperidone than lurasidone and iloperidone.
• Haloperidol had similar benefits but more adverse events than olanzapine and risperidone.
• Psychosocial treatments improved outcomes versus usual care: assertive community care (core illness symptoms, function), cognitive behavioral therapy (core illness symptoms, function, quality of life), cognitive remediation (core illness symptoms), family interventions (core illness symptoms, function, relapse), illness self-management (core illness symptoms), psychoeducation (core illness symptoms, function, relapse), social skills training (core illness symptoms, function), and supported employment (core illness symptoms, employment).
• For more, see https://effectivehealthcare.ahrq.gov/topics/schizophrenia-adult/research-2017/

Spanish Consumer Summaries Now Available

Translations of our consumer summaries are now available in Spanish:

• Ácidos grasos omega-3 y la enfermedad cardiovascular
  (Omega-3 Fatty Acids and Cardiovascular Disease)
• Tratamiento y prevención de infecciones por C. difficile
  (Treating and Preventing C. difficile Infections)
• Manejo del insomnia
  (Managing Insomnia Disorder)

About us: AHRQ’s Effective Health Care Program is committed to providing the best available evidence on the outcomes, benefits and harms, and appropriateness of drugs, devices, and health care services and by helping health care professionals, patients, policymakers, and health care systems make informed health care decisions. The program partners with research centers, academic institutions, health professional societies, consumer organizations, and other stakeholders to conduct research, evidence synthesis, evidence translation, dissemination, and implementation of research findings.

To learn more: https://effectivehealthcare.ahrq.gov/

Contact us at epc@ahrq.hhs.gov

EHC Program Update: Bipolar Disorder Draft Report; Schizophrenia Final Report; Spanish Consumer Summaries for Omega-3 Fatty Acids and CVD, C. diff, and Insomnia